TerminatedNot Applicable

COPD Exacerbation Blood and Urine Biomarkers Study

Stopped: Difficulty enrolling

United States7 participantsStarted 2018-06-07

Plain-language summary

This will be a prospective study examining serum levels of MMP-13 and alpha-1 antitrypsin as well as other biomarkers as well as urine biomarkers of smoking status and collagen degradation in the COPD patient population. Serum and urine biomarkers at baseline and after COPD exacerbations will be assessed against change in lung function as measured by pulmonary function testing.

Who can participate

Age range35 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed with COPD (FEV1 \<80% AND FEV1/FVC \< 70%) * Ages 35-80yrs Exclusion Criteria: * History of Asthma * Bronchiectasis * Carcinoma of the bronchus * Recent COPD exacerbation or pulmonary infection (less than 1 month) * Other significant respiratory disease * Pregnancy

What they're measuring

MMP13 to Alpha-1 antitrypsin ratios

Timeframe: 1 year

Trial details

NCT IDNCT03823443

SponsorColumbia University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-08-22

View on ClinicalTrials.gov More Chronic Obstructive Pulmonary Disease trials